Biodexa Pharmaceuticals’ (BDRX) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of Biodexa Pharmaceuticals (NASDAQ:BDRX) in a report published on Tuesday morning,Weiss Ratings reports.

Separately, Wall Street Zen downgraded Biodexa Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 2nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Stock Up 2.8%

Shares of BDRX opened at $8.34 on Tuesday. Biodexa Pharmaceuticals has a one year low of $5.00 and a one year high of $92.00. The business has a fifty day moving average of $6.68 and a 200 day moving average of $9.82.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.